Navigation Links
ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver

arma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the company's website at http://www.viropharma.com .

Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. .including those relating to the company's progress of its HCV clinical development program as well as its ability to develop an effective small molecule antiviral treatment for HCV disease. Our actual results could differ materially from those results expressed in, or implied by, these forward-looking statements.. Conducting clinical trials for investigational pharmaceutical products is subject to risks and uncertainties. Further testing such as the ongoing Phase 2 clinical studies of HCV-796 with pegylated interferon, may not support any or all of the statements in this press release. There can be no assurance that ViroPharma's additional HCV studies will yield positive results, or that ViroPharma will be successful in gaining regulatory approval of any of its HCV product candidates. These factors, and other factors, including, but not limited to those described in ViroPharma's quarterly report on Form 10-K for the year ended December 31, 2006 filed with the Securities and Exchange Commission, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements.

CONTACT: Vincent J. Milano, Vice President, Chief Operating Officer, ChiefFinancial Officer and Treasurer, +1-610-321-6225, or William C. Roberts,Senior Director, Corporate Communications, +1-610-321-6288, both ofViroPharma Incorporated

Web site:




Page: 1 2 3 4 5 6

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:12/16/2009)... Accuray Incorporated (Nasdaq: ARAY ), a ... that its president and chief executive officer, Euan S. ... Annual J.P. Morgan Healthcare Conference in San Francisco on ... ET. ,, A live webcast of each presentation ... of the Company,s Web site at http://www.accuray.com . ...
(Date:12/16/2009)... Dec. 16 DATATRAK International, Inc. ... focused on global eClinical solutions for the ... of its version 9.0 eClinical Software. ... for product and service delivery and introduces ... Knowledge(TM) offering: the DATATRAK Learning Center(TM) and ...
(Date:12/16/2009)... Bulletin Board: HEWA) an online U.S. mail-order pharmacy, today ... annum short term debt financing. The structure of ... with accrued interest and principal repayable in one year. ... principal repayable in one year from its funding, is ... calendar month prior to December 15, 2010. ,, ...
Breaking Medicine Technology:Accuray Incorporated to Present at 28th Annual J. P. Morgan Healthcare Conference 2DATATRAK's eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM) 2DATATRAK's eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM) 3DATATRAK's eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM) 4HealthWarehouse.com, Inc. Secures $1 Million in Debt Financing 2The therapeutic benefits of the human animal bond 62252 1The therapeutic benefits of the human animal bond 62252 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 10921 1French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 10921 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 10921 3French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 10921 4Register now online for the World Congress on Osteoporosis 2010 IOF WCO ECCEO10 10917 1
(Date:12/16/2009)... Immucor, Inc. (Nasdaq: BLUD ), a ... blood transfusion industry, today announced that Paul D. Mintz, ... new independent director, effective January 1, 2010. ,, ... transfusion medicine for more than 30 years. He is ... University of Virginia School of Medicine. He also serves ...
(Date:12/16/2009)... Dec. 16 As a result of C3: ... new peer reviewed cancer research program is included in ... ,, This new cancer research program will research cancers, ... breast, prostate, lung and ovarian cancer research programs run ... ,, The $15 million in funding for ...
(Date:12/16/2009)... by the Wellcome Trust Sanger Institute announce the first ... are caused by mutations in the DNA of cancer ... studies, of a malignant melanoma and a lung cancer, ... in the genomes of two cancers. , Lung cancer ... all are associated with smoking. The number of mutations ...
(Date:12/16/2009)... Coalition Urges Lawmakers to Ensure and Encourage Access to Quality, Cost-Effective ... ... -- For months, members of Congress have debated the best ways ... part of health care reform. An important part of the ... full range of health care providers besides doctors of medicine (MDs) ...
(Date:12/16/2009)... campaign , ... Englewood, CO (Vocus) ... Hotbed Campaign as its largest yearly promotion for the ... MassBio and showcases 37 Massachusetts companies across biotechnology, pharmaceutical ... on an electronic and printed map that is ...
Breaking Medicine News(10 mins):Health News:Immucor Appoints New Board Director 2Health News:House Creates New Cancer Research Program 2Health News:House Creates New Cancer Research Program 3Health News:Lung cancer and melanoma laid bare 2Health News:Lung cancer and melanoma laid bare 3Health News:Lung cancer and melanoma laid bare 4Health News:Lung cancer and melanoma laid bare 5Health News:Lung cancer and melanoma laid bare 6Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 2Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 3Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 4Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 5Health News:Thriving Bioscience Region Leaves Its Mark 2
... use of DDT indoors, as a positive move to combat ... was found to be harmful for wildlife and birds. ... World Health Organization (WHO) malaria department 'One of the best ... Of the dozen pesticides WHO has approved as safe for ...
... just got for the new school year might seem harmless, ... neck ailments if not// loaded or worn correctly, according to ... at University of the Sciences in Philadelphia. ,“While ... after day stress caused by a backpack that is too ...
... Awareness Month and the American Society for Therapeutic Radiology ... when it comes to// prostate cancer awareness, screening and ... 234,460 new cases of prostate cancer will be diagnosed ... Society. Fortunately, screening for prostate cancer is relatively easy. ...
... A new treatment for malaria has been developed with the ... young lives in Africa. A system based on fluid// replacement ... Imperial College in London in collaboration with the Wellcome Trust ... the lives of millions of kids, who die every year ...
... mumps has affected seven students at Wheaton College and has ... was identified on September 7. Mumps causes// swollen glands close ... ,"We think we have a good handle on things, ... Chugh, medical officer for the DuPage County Health Department. "We ...
... Hospital in Birmingham to meet with staff and patients and also ... ,Seizing the opportune moment, the Prime Minister was targeted ... the privatization plan of the health service. ,To the ... make changes, people will say it's the end of the NHS ...
Other Medicine News:Health News:Lighten Up! Heavy Backpacks a Weighty Load for Children to Bear 2Health News:Do You Know the Signs and Symptoms of Prostate Cancer? 2Health News:A Novel approach in Malaria treatment 2
... Unparalleled Comfort Pick one of our pipettors ... the trigger and ejector positionsright where they should ... are ergonomically designed to help avoid repetitive stress ... Productivity In The Palm Of Your Hand ...
... Pick one of our pipettors up and ... and ejector positionsright where they should beeven if ... designed to help avoid repetitive stress injuries caused ... The Palm Of Your Hand Start dispensing ...
... BioControl multichannel has the same ... channel model. The same universal ... and five single channel tip ... a recharge and storage stand ...
... The Research pro Electronic Pipette is ... the laboratory. Its easy-to-follow display, ergonomically-placed operating ... pipetting, dispensing, reverse pipetting and diluting make ... the simple functions of a manual pipette ...
Medicine Products: